SymBio Pharmaceuticals Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SymBio Pharmaceuticals Limited
ProQR’s Axiomer platform can enable single nucleotide RNA editing, an approach that could address thousands of disease-causing genetic mutations, the company says.
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- SymBio Pharma USA, Inc.